Tatiana Prowell, MD
Johns Hopkins Medicine
U.S. Food & Drug Administration
Tatiana Prowell, MD, is a board-certified hematology and medical oncology physician
in the Division of Women’s Malignancies at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and an Associate Professor of Oncology at Johns Hopkins University in Baltimore. She currently serves as a Medical Officer and Scientific Lead for Breast Cancer in the Office of Hematology/Oncology Products at the US Food and Drug Administration (FDA).
Dr Prowell earned her medical degree from Johns Hopkins University School of Medicine in Baltimore, where she was elected to the Phi Beta Kappa and Alpha Omega Alpha honor societies. She completed a residency in internal medicine at Johns Hopkins Hospital and fellowship in medical oncology within the Breast Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. She is the recipient of a Young Investigator Award given by the American Society of Clinical Oncology (ASCO), twice recipient of the Pearl M. Stetler Research Fund for Women for her breast cancer research, and triple recipient of the US FDA’s Excellence in Communication Award. Recently, Dr Prowell helped to pioneer a pathway to accelerated approval for drugs used to treat patients with high-risk, early-stage breast cancers, such as triple-negative breast cancer, in the neoadjuvant setting.
She has published at least 24 peer-reviewed articles. Dr Prowell’s clinical research focus includes triple-negative breast cancer, development of novel agents for breast cancer treatment, neoadjuvant therapy for breast cancer, and the unique challenges of breast cancer in younger women.
- Professional Vignette: The Importance of Women’s Leadership in Healthcare and Oncology